New York, Jan 13, 2026, 05:42 (ET) — Premarket
- ImmunityBio shares were down 0.8% in premarket trading at $2.57
- Stock is coming off a sharp Monday jump as JPM Healthcare Conference week gets underway
- Investors are watching for headlines from a Jan. 14 U.S.-Saudi biotech summit in San Francisco
ImmunityBio shares were down 0.8% in premarket trading on Tuesday at $2.57, as of 5:00 a.m. ET. Around 13,000 shares had traded by that point, according to Public.com data. Premarket trading runs before the regular U.S. session opens at 9:30 a.m. ET and can be choppy.
The biotech’s latest catalyst is a conference-week push into the spotlight. ImmunityBio and NantWorks on Monday announced an inaugural U.S.-Saudi Biotech Alliance Summit in San Francisco on Jan. 14, alongside the annual J.P. Morgan Healthcare Conference. “This initiative is about moving from strategy to execution,” founder Patrick Soon-Shiong said. Business Wire
ImmunityBio is one of many healthcare names using the J.P. Morgan gathering — scheduled for Jan. 12-15 in San Francisco — to meet investors and hunt for partners, according to the company’s website. The event can tighten timelines fast, especially for smaller biotechs that live and die on access to capital.
The stock jumped about 10.7% on Monday and ended at $2.59, before easing in early trade on Tuesday.
That leaves the shares in the hands of headline traders. For longer-term investors, the question is whether JPM-week meetings translate into anything real — a partner, manufacturing capacity, maybe funding.
On Wall Street, four analysts tracked by Public.com rate ImmunityBio a “Strong Buy” and put an average price target at $11.50. Those targets can swing hard in biotech, and they tend to bake in wins that still have to be earned. Public
In its latest quarterly filing, ImmunityBio reported cash and restricted cash of $61.3 million at Sept. 30, down from $143.9 million at the start of the year. It said it expects existing cash, product sales, equity offerings and potential borrowing from affiliated entities to fund operations for at least the next 12 months.
But conference headlines can fade once the meetings end. Investors are still looking for clearer signs that ImmunityBio can scale, and any hint of a slower rollout or fresh financing could hit the shares.
ImmunityBio’s premarket move was small, yet it underlines how attention is clustering around this week’s calendar. Volume after the open will matter more than a few early prints.
The next hard date is Jan. 14, when the summit is set to run in San Francisco. Traders will also watch the rest of the J.P. Morgan Healthcare Conference through Jan. 15 for any filings or deal disclosures.
